Company intelligence / Profile preview

Archimedes Development

Reading, Berkshire, United Kingdompmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~200
Development stage: Phase 3

Overview

Archimedes Pharma has successfully developed and commercialized products including PecFent/Lazanda (fentanyl nasal spray) for breakthrough cancer pain, which received FDA approval in 2011 and European marketing authorization in 2010. The company has also shown positive proof-of-concept results for intranasal apomorphine for Parkinson's disease and intranasal diazepam for epilepsy.

Therapeutic areas: OtherOncologyNeurology
Modalities: Small moleculesDrug delivery systems
Industry: Drug Discovery Services

Drug pipeline

3 assets

Nefecon

Phase 3

Indications: IgA nephropathy

2 more assets in the full pipeline.

Request access →

Partnerships

proteanTecs

Beyond the preview

Go deeper on Archimedes Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Archimedes Development.

Explore the full profile